NCT00650689View on ClinicalTrials.gov

Ezetimibe Plus Atorvastatin Versus Atorvastatin in Untreated Subjects With Primary Hypercholesterolemia and Coronary Heart Disease (P03396)

PHASE3CompletedINTERVENTIONAL
Enrollment

122

Participants

Timeline

Start Date

May 31, 2003

Primary Completion Date

December 31, 2004

Study Completion Date

December 31, 2004

Conditions
HypercholesterolemiaAtherosclerosisCoronary Artery Disease
Interventions
DRUG

Ezetimibe + Atorvastatin

oral tablets: ezetimibe 10 mg + atorvastatin 10 mg once daily for 6 weeks

DRUG

Atorvastatin

oral tablets: atorvastatin 10 mg + ezetimibe placebo once daily for 6 weeks

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Organon and Co

INDUSTRY

NCT00650689 - Ezetimibe Plus Atorvastatin Versus Atorvastatin in Untreated Subjects With Primary Hypercholesterolemia and Coronary Heart Disease (P03396) | Biotech Hunter | Biotech Hunter